[FLXN] Flexion Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 20.71 Change: 2.14 (11.52%)
Ext. hours: Change: 0 (0%)

chart FLXN

Refresh chart

Strongest Trends Summary For FLXN

FLXN is in the medium-term up 28% above S&P in 1 year. In the long-term down -50% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.24% ROE-21.88% ROI
Current Ratio32.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.69 M Cash From Investing Activities-62.47 M Cash From Operating Activities-9.98 M Gross Profit
Net Profit-9.17 M Operating Profit-9.01 M Total Assets141.02 M Total Current Assets134.24 M
Total Current Liabilities4.16 M Total Debt Total Liabilities4.19 M Total Revenue
Technical Data
High 52 week19.6 Low 52 week9.07 Last close14.15 Last change2.39%
RSI43.06 Average true range0.79 Beta1.41 Volume629.96 K
Simple moving average 20 days1.12% Simple moving average 50 days9.85% Simple moving average 200 days14.99%
Performance Data
Performance Week4.12% Performance Month-2.82% Performance Quart28.64% Performance Half34%
Performance Year-23.01% Performance Year-to-date25% Volatility daily2.59% Volatility weekly5.79%
Volatility monthly11.87% Volatility yearly41.12% Relative Volume286.22% Average Volume623.19 K
New High New Low


2020-05-28 09:13:01 | Flexion FLXN Soars: Stock Adds 6.6% in Session

2020-05-21 12:02:00 | Why Flexion Therapeutics Is Tumbling 10% Today

2020-05-21 07:30:10 | Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

2020-05-20 16:01:10 | Flexion Therapeutics Announces Proposed Public Offering of Common Stock

2020-05-14 09:27:01 | How Flexion Therapeutics FLXN Stock Stands Out in a Strong Industry

2020-05-13 17:00:20 | Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference

2020-05-09 15:00:34 | Flexion Therapeutics Inc FLXN Q1 2020 Earnings Call Transcript

2020-05-08 16:14:23 | Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-07 16:01:10 | Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights

2020-05-05 09:00:10 | Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting

2020-05-01 09:00:10 | Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020

2020-04-30 16:30:10 | Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020

2020-04-27 07:30:10 | Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain

2020-04-07 16:30:10 | Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

2020-04-03 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-01 07:00:10 | Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic

2020-03-14 08:55:17 | Flexion Therapeutics, Inc. Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

2020-03-13 01:16:43 | Edited Transcript of FLXN earnings conference call or presentation 12-Mar-20 8:30pm GMT

2020-03-12 18:35:10 | Flexion Therapeutics FLXN Reports Q4 Loss, Tops Revenue Estimates

2020-03-12 16:01:10 | Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results

2020-03-12 07:37:17 | The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

2020-03-11 16:30:10 | Flexion Therapeutics Names Melissa Layman Chief Commercial Officer

2020-03-06 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-03-05 12:30:05 | Will Flexion Therapeutics FLXN Report Negative Earnings Next Week? What You Should Know

2020-03-04 16:30:10 | Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020

2020-02-24 16:30:10 | Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference

2020-02-20 12:31:05 | Flexion Therapeutics FLXN May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2020-02-20 07:12:44 | Have Insiders Been Buying Flexion Therapeutics, Inc. NASDAQ:FLXN Shares?

2020-02-07 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-01-28 14:36:06 | 5 'Strong Buy' Biotech Stocks to Buy for 2020

2020-01-15 06:34:45 | When Will Flexion Therapeutics, Inc. NASDAQ:FLXN Turn A Profit?

2020-01-13 08:30:10 | Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

2020-01-09 16:01:10 | Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

2020-01-03 16:30:10 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-01-01 18:00:09 | Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

2019-12-31 09:39:02 | Is the Options Market Predicting a Spike in Flexion FLXN Stock?

2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA

2019-12-27 14:53:11 | Flexion Therapeutics soars on FDA label change approval

2019-12-27 14:14:00 | Flexion Therapeutics shares soar after FDA approves change to label on knee pain treatment

2019-12-27 10:33:25 | Flexion Analysts Say Long-Delayed Zilretta Label Expansion A Relief For Investors

2019-12-27 08:46:30 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB

2019-12-27 08:02:00 | Flexion Therapeutics stock soars 24% premarket as FDA approves label change for OA keen pain therapy

2019-12-27 07:59:52 | The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

2019-12-27 05:47:00 | Flexion Surges on FDA Label-Update Approval, Analyst Price-Target Lift

2019-12-26 16:15:10 | Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® triamcinolone acetonide extended-release injectable suspension Product Label

2019-12-17 07:30:10 | Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in OA of the Shoulder and Adhesive Capsulitis

2019-12-12 15:42:53 | Should You Buy Flexion Therapeutics Inc FLXN?

2019-12-12 13:12:36 | Should Investors Up the Ante on These 3 “Strong Buy” Stocks?

2019-12-10 09:00:10 | Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder